

What is claimed is:

1. KM-110 extract from Korean mistletoe having immunostimulating and antitumoral activity.
2. A method for isolating KM-110 extract from Korean mistletoe comprising the steps of:
 - a) cutting and slicing Leaf, stem and fruit of Korean mistletoe with froze or not-froze;
 - b) adding distilled water to them, agitating and centrifuging them; and,
 - c) filtering subsequently a supernatant obtained from the step b) by membrane filter with various size.
3. A use of antitumor agent and/or immunity enhancer of KM-110 of claim 1.
4. A protein KM-AS isolated from Korean mistletoe having immunostimulating and antitumoral activity.
5. A method for preparing protein KM-AS comprising the steps of:
 - a) cutting Leaf, stem and fruit of Korean mistletoe;
 - b) adding phosphate buffer containing NaCl to them and agitating them; and,
 - c) adding ammonium sulphate powder to a mixture and then agitating and precipitating saturated ammonium sulphate obtained from the above.
6. A use of antitumor agent and/or immunity enhancer of protein KM-AS from Korean mistletoe of claim 4.
7. A lectin KML-C from Korean mistletoe having immunostimulating and antitumoral activity.
8. A method for preparing lectin KML-C of claim 7 comprising the steps of:
 - a) passing through protein KM-AS from Korean mistletoe to column chromatography with sepharose 4B hydrolyzed by HCl;
 - b) washing the column and then eluting the column bound materials containing lactose with PBS; and,
 - c) dialyzing the materials to remove lactose and then obtaining the resulted lectin.

9. A use of antitumor agent and/or immunity enhancer of lectin KML-C from Korean mistletoe.
10. Lectins KML-IIU and KML-IIL with molecular weights of 61.8 kD and 56.4 kD, which are isolated from Korean mistletoe.
11. A method for preparing the lectin KML-IIU or KML-IIL of claim 3, in which a lectin fraction KML-C extracted from Korean mistletoe is allowed to flow through an immuno-affinity column eluting with a PBS buffer or a glycine-HCl buffer(pH2.7), the immuno-affinity column being a HiTrip NHS activated affinity column in which 9H7-D10 antibody is immobilized.
12. A use of antitumor agent and/or immunity enhancer of lectins KML-IIU and/or KML-IIL from Korean mistletoe.
13. Coding genes of lectins KML-IIU and/or KML-IIL of claim 10.
14. The genes as set forth in claim 13, wherein the genes have sequences of lectin KML-IIU of SEQ. NO.1 and KML-IIL of SEQ. NO. 2.
15. A protein fraction KMHBP, having an activity of inducing IFN- γ , which is prepared by binding a protein fraction C-free AS to a heparin column and eluting it with 10 mM-1 M of NaCl, the C-free AS being a portion of a protein KM-AS free of a lectin component KML-C.
16. An immunity enhancer of antitumoral activity, comprising as an effective ingredient the protein fraction KMHBP of claim 15.
17. A fraction KM, having immunity enhancement activity and antitumoral activity, which is prepared by a lectin component KML-C and the protein fraction KMHBP of claim 7.
18. A use of antitumoral agent and/or immunity enhancer of the fraction KM of claim 17.